Pharmaceutical drug testing is the meticulous exploration of a compound's safety, efficacy, and potential side effects, marking a pivotal phase in the journey from discovery to market. This intricate process unfolds in a series of carefully designed trials, each serving a distinct purpose in unravelling the compound's impact on the human body. The journey begins with preclinical testing, where researchers delve into the compound's behaviour in the laboratory and animal models. This phase unveils insights into safety profiles, potential dosage ranges, and initial efficacy.
Upon successful preclinical evaluations, the compound progresses to clinical trials, a multi-phase endeavour involving human subjects. Phase 1 focuses on safety and dosage, Phase 2 delves into efficacy, and Phase 3 expands to larger populations, further validating the drug's effectiveness and monitoring for rare side effects. Regulatory bodies meticulously review the accumulated data, assessing the compound's risk-benefit profile before granting approval for market release. Post-marketing surveillance continues the scrutiny, ensuring ongoing safety and efficacy monitoring.
The evolution of pharmaceutical drug testing mirrors a meticulous orchestration of scientific inquiry, ethical considerations, and regulatory diligence. Each trial, from petri dish to patient, contributes to the collective endeavour of bringing safe and effective medications to those in need.
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami School of Medicine, United States
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Tailored cellular environments to enable drug design
Lan Wang, Paretor LLC, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, InMedStar and Biona, Russian Federation
Title : Precision diagnostics: Effectiveness of innovative imaging technologies for early detection of lung cancers
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Design and characterization of gum arabic buccal films for protein drug delivery
Krisztian Pamlenyi, University of Szeged, Hungary
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand